ARGX-113
ARGX-113-2005
Phase 3 small_molecule active
Quick answer
ARGX-113 for Primary Immune Thrombocytopenia is a Phase 3 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Argenx
- Indication
- Primary Immune Thrombocytopenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active